Merck Retained Earnings (Accumulated Deficit) 2010-2024 | MKKGY
Merck retained earnings (accumulated deficit) from 2010 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
- Merck retained earnings (accumulated deficit) for the quarter ending June 30, 2024 were $23.023B, a 6.85% increase year-over-year.
- Merck retained earnings (accumulated deficit) for 2023 were $21.893B, a 12.54% increase from 2022.
- Merck retained earnings (accumulated deficit) for 2022 were $19.453B, a 8.64% increase from 2021.
- Merck retained earnings (accumulated deficit) for 2021 were $17.905B, a 26.63% increase from 2020.
Merck Annual Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2023 |
$21,893 |
| 2022 |
$19,453 |
| 2021 |
$17,905 |
| 2020 |
$14,139 |
| 2019 |
$12,888 |
| 2018 |
$14,792 |
| 2017 |
$11,191 |
| 2016 |
$8,907 |
| 2015 |
$7,795 |
| 2014 |
$8,640 |
| 2013 |
$7,342 |
| 2012 |
$6,094 |
| 2011 |
$12,080 |
| 2010 |
$ |
| 2009 |
$ |
Merck Quarterly Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2024-06-30 |
$23,023 |
| 2024-03-31 |
$22,833 |
| 2023-12-31 |
$21,893 |
| 2023-09-30 |
$22,542 |
| 2023-06-30 |
$21,546 |
| 2023-03-31 |
$20,663 |
| 2022-12-31 |
$19,453 |
| 2022-09-30 |
$18,961 |
| 2022-06-30 |
$19,172 |
| 2022-03-31 |
$18,460 |
| 2021-12-31 |
$17,905 |
| 2021-09-30 |
$17,635 |
| 2021-06-30 |
$17,030 |
| 2021-03-31 |
$16,289 |
| 2020-12-31 |
$14,139 |
| 2020-09-30 |
$14,707 |
| 2020-06-30 |
$12,941 |
| 2020-03-31 |
$13,214 |
| 2019-12-31 |
$12,888 |
| 2019-09-30 |
$12,581 |
| 2019-06-30 |
$12,825 |
| 2019-03-31 |
$14,441 |
| 2018-12-31 |
$14,792 |
| 2018-09-30 |
$12,448 |
| 2018-06-30 |
$1,616 |
| 2018-03-31 |
$12,624 |
| 2017-12-31 |
$11,191 |
| 2017-09-30 |
$11,143 |
| 2017-06-30 |
$9,719 |
| 2017-03-31 |
$9,133 |
| 2016-12-31 |
$8,907 |
| 2016-09-30 |
$9,206 |
| 2016-06-30 |
$8,802 |
| 2016-03-31 |
$8,402 |
| 2015-12-31 |
$7,795 |
| 2015-09-30 |
$8,189 |
| 2015-06-30 |
$7,739 |
| 2015-03-31 |
$7,657 |
| 2014-12-31 |
$8,640 |
| 2014-09-30 |
$8,813 |
| 2014-06-30 |
$8,783 |
| 2014-03-31 |
$7,837 |
| 2013-12-31 |
$7,342 |
| 2013-09-30 |
$6,884 |
| 2013-06-30 |
$6,416 |
| 2013-03-31 |
$6,387 |
| 2012-12-31 |
$6,094 |
| 2012-09-30 |
$10,863 |
| 2012-06-30 |
$11,131 |
| 2012-03-31 |
|
| 2011-12-31 |
$12,080 |
| 2011-09-30 |
|
| 2011-06-30 |
$12,215 |
| 2011-03-31 |
|
| 2010-12-31 |
|
| 2010-09-30 |
$12,781 |
| 2010-06-30 |
|
| 2010-03-31 |
|
| 2009-12-31 |
|
| 2009-09-30 |
|
| 2009-06-30 |
|
| 2009-03-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-DRUGS |
$21.306B |
$22.719B |
|
Merck is a global pharmaceutical and chemical company. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.
|
